Inhibition of Adrenergic Function in the Treatment of Hypertension
- 1 June 1974
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 133 (6) , 1033-1048
- https://doi.org/10.1001/archinte.1974.00320180151013
Abstract
With the availability of effective antihypertensive drugs, it has become possible to reduce significantly the morbidity and mortality from cardiovascular complications of hypertension. Among the more potent agents that maintain a reduced arterial blood pressure are those that inhibit sympathetic activity; this inhibition may be achieved at practically any anatomical level of adrenergic function. However, for these compounds to maintain and enhance their effectiveness, they must be used in conjunction with diuretics. The following discussion reviews each of these adrenolytic agents, describing their respective mechanisms of action, hemodynamic effects, their clinical uses, and side effects.This publication has 79 references indexed in Scilit:
- Neural IntegrationScience, 1993
- Cardiovascular Pathophysiology of Essential HypertensionDrugs, 1985
- Clinical Significance of Hemodynamic Findings in HypertensionChest, 1973
- Dependence of Arterial Pressure on Intravascular Volume in Treated Hypertensive PatientsNew England Journal of Medicine, 1972
- Plasma volume changes with long-term beta-adrenergic blockadeAmerican Heart Journal, 1971
- Clinical-Physiological Correlations in the Development of Hypertensive Heart DiseaseCirculation, 1971
- Plasma Volume Expansion Resulting from Interference with Adrenergic Function in Normal ManCirculation, 1968
- Five year survival of consecutive patients with malignant hypertension treated with antihypertensive agentsThe American Journal of Cardiology, 1960
- Five-year survival of patients with malignant hypertension treated with antihypertensive agentsAmerican Heart Journal, 1960
- Results of Treatment in Malignant HypertensionBMJ, 1959